Walden Group Healthcare M&A Blog

Walden Group Arranges the sale of JoViPak Corporation to BSN Medical GmbH & Co. KG

09/09/2015
The Walden Group advised JoViPak Corporation and arranged for its sale to BSN Medical GmbH & Co. KG,, a $850m manufacturer of products for wound care, vascular disease, lymphology and non-invasive orthopaedic conditions. JoViPak pioneered the market for night-time lymphedema garments to manage lymphatic disorders, an underserved, yet...
Read More
Drugs for Rare Diseases, Cancer and other Conditions Continue to Enjoy High Pricing, but For How Long?

09/01/2015
The recent $3.2b healthcare M&A purchase of Synageva BioPharma Corp. by Alexion Pharmaceuticals again put the spotlight on the high cost of specialty drugs. Synageva's lead candidate, Kanuma, is designed to treat lysosomal acid lipase deficiency, a genetic disease in which people do not produce enough of a certain enzyme. Infants with...
Read More
The Laboratory Diagnostics Segment Settles Down and Regroups Using Data Analytics and Tools for Providers and Consumers

08/10/2015
After several years of government reimbursement pressure, headwinds are beginning to abate. Given the aging population, the significant positive impact in vitro diagnostics have on the medical care and controlling costs, the diagnostics market is expect to grow. This is especially the case in regard to molecular diagnostics and genetic...
Read More
Healthcare Insurers Are Merging in light of The Supreme Court's Affirmation of the Affordable Care Act

08/04/2015
In June 2015, the Supreme Court of the United States affirmed the Affordable Care Act in King v. Burwell. While the Republicans may continue to try to change some provisions, the Court clarified much of the uncertainty surrounding the fate of the ACA. The ACA provides for a major expansion in the number individuals entitled to insurance...
Read More
Clinical Diagnostic M&A Developments

07/08/2015
Composition The U.S. clinical testing industry consists of two segments: (a) hospital inpatient and outpatient testing (40%) and (b) commercial clinical laboratories, physician-office laboratories and other locations, as well as hospital outreach testing (60%).Hospital-based and affiliated laboratories account for ~60% of the total industry;...
Read More